 SHANGHAI, China., and GAITHERSBURG, MD, April 14, 2021 GLOBE NEWSWIRE -- I-Mab the Company Nasdaq: IMAB, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its abstract on proprietary and highly differentiated CD73 antibody uliledlimab also known as TJD5, or TJ004309 has been selected for detailed poster presentation at the 2021 American Society of Clinical Oncology ASCO Annual Meeting, taking place virtually June 4-8, 2021. 